Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
Byline: GLORIA GONZALEZ Pharmaceutical manufacturer Merck & Co.'s decision to offer pricing incentives to encourage insurers and pharmacy benefit managers to favor its brand-name drug Zocor over recently introduced generic versions has initiat Byline: GLORIA GONZALEZ Pharmaceutical manufacturer Merck &...
A recent policy change by Merck to offer greater discounts for its cholesterol-lowering drug Zocor has employers, pharmacy benefit managers and insurers faced with making a tough decision: Should they follow what has been general tradition to this point a A recent policy change by Merck to offer greater discounts...
A recent change in policy adopted by large pharmaceutical firm Merck to offer greater discounts for its cholesterol-lowering drug Zocor has given employer-clients, pharmacy benefit managers and insurers a tough benefit design decision: Should they stick w A recent change in policy adopted by large pharmaceutical firm Merck to offer...
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Novartis' generic unit, Sandoz, Inc., has filed a complaint in the United States District Court for the District of Columbia, seeking approval of its generic ZocorR products in the face of an April 30, 2006 decision of the same...
Byline: GLORIA GONZALEZ The recent expiration of the patents on blockbuster prescription drugs Zocor and Zoloft represents a tremendous opportunity to reinvigorate generic drug promotion programs, insurers and pharmacy benefit managers say. The Byline: GLORIA GONZALEZ The...
MERCK & Co. Inc. has received FDA approval for changes to the label for its cholesterol-lowering drug Zocor ... MERCK & Co. Inc. has received FDA approval for changes to the label for its cholesterol-lowering drug Zocor simvastatin to recommend a 40mg starting dose...
HARTFORD, Conn. -- Aetna (NYSE:AET) Pharmacy Management APM today announced it will encourage members to use generics first when the patent for Zocor expires this Friday. Aetna is supporting Teva Pharmaceuticals (NASDAQ:TEVA), which manufactures the generic alternative Simvastatin, to help provide customers with continued access to affordable, appropriate prescription drug...
What's for lunch today? Pizza and potato chips? Fish and salad? We love choices at mealtime, but many of us make poor ones by eating too many fatty foods. That's why millions of Americans have high cholesterol, a major risk factor for heart disease and st What's for lunch today?...
Pfizer's Lipitor Provides Greater Reductions in Heart Attack, Stroke and Cardiovascular Procedures at an Overall Cost Savings Compared to Zocor, New...
May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva Pharmaceutical are likely to get a windfall by having six months without competition to sell their generic versions of Merck's blockbuster cholesterol drug Zocor. May 3--NEW DELHI -- Ranbaxy and Israeli generic major Teva...
the landmark Scandinavian Simvastatin Survival Study (4S) demonstrate that treating elderly patients who have heart disease and high cholesterol with ZocorR simvastatin reduced death due to heart disease by 43 percent and reduced death from any cause by 34 percent.
VANCOUVER, British Columbia -- Forbes Medi-Tech Inc. (NASDAQ:FMTI)(TSX:FMI) today announced the results from two pre-clinical studies involving the Company's cholesterol-lowering drug, FM-VP4. The first study was designed to assess the effects of Forbes' cholesterol-lowering drug candidate, FM-VP4, in combination with Simvastatin ZocorRi from Merck (NYSE:MRK),...
MERCK & Co. Inc. reports that changes to the existing label for cholesterol-lowering drug Zocor simvastatin further clarify the risk of myopathy and rhabdomyolysis, particularly with higher doses and when used with certain drugs. Merck reques MERCK & Co. Inc. reports that changes to...
New Lipitor Study Demonstrates That Intensive LDL Cholesterol Lowering in Heart Disease Patients Can Reduce Cardiovascular Events, Pfizer Says DALLAS, Nov. 15 -- Patients who had a previous heart attack and took Pfizer Inc's cholesterol- ...
MERCK & CO. Inc.'s Zocor simvastatin, a cholesterol-lowering drug, has received FDA approval ... MERCK & CO. Inc.'s Zocor simvastatin, a cholesterol-lowering drug, has received FDA approval as the first cholesterol-modifying drug indicated to increase HDL cholesterol, or good cholesterol.
Apr. 24--Moving to fend off new competition, Merck & Co. plans to seek approval later this year to sell a higher dosage of its best-selling cholesterol fighter, Zocor. Apr. 24--Moving to fend off new competition, Merck & Co. plans to seek...
Apr. 17--Merck & Co., the nation's biggest drug maker, yesterday reported that first-quarter earnings rose 18 percent on the strength of several new medications, particularly its cholesterol fighter, Zocor. Apr. 17--Merck & Co., the nation's biggest drug maker, yesterday reported...
Choose up to 5" more legroom with Economy Plus. Starting at $14.
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
